Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2014-09-24 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Exercise of Options
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces the allotment and admission to trading of new ordinary shares following the exercise of options. This is a corporate action announcement related to share capital. While it involves share issuance, the primary context is a general regulatory news service announcement. Given the explicit RNS branding and the nature of the announcement (a short update on share allotment), the most appropriate classification is Regulatory Filings (RNS), as it is a standard regulatory news service release, even though it touches upon share capital changes.
2014-09-24 English
Annual Report and Accounts
Report Publication Announcement Classification · 99% confidence The document is very short (1812 characters) and explicitly states that the 'Annual Report and Accounts for the year ended 30 June 2014 are available on the Company's website' and provides a link. It also mentions that the shareholder copy will be posted later with the Notice of the Annual General Meeting. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document announces the publication of a report rather than containing the full report itself, it should be classified as a Report Publication Announcement (RPA). The presence of the RNS Number further supports this being a regulatory announcement about a report release.
2014-09-24 English
Final Results
Earnings Release Classification · 100% confidence The document explicitly states it contains 'Preliminary results for the year ended 30 June 2014' and provides detailed financial highlights, commentary from the CEO and Chairman, and a full financial review covering revenue, profit, and investment for the full fiscal year. This content structure is characteristic of a comprehensive annual financial report, although it is labeled 'preliminary'. Since the document covers the full fiscal year (12 months) and contains detailed financial statements/reviews, it aligns best with the Annual Report category (10-K), even if it might precede the final audited 10-K filing. Given the comprehensive nature and full-year scope, 10-K is the most appropriate classification over a simple Earnings Release (ER) or Interim Report (IR). The RNS number suggests it was also released via the Regulatory News Service, but the content itself is the annual results. FY 2014
2014-09-22 English
Shareholder update
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number (6741Q) and the date (04 September 2014). The text explicitly states that Allergy Therapeutics plc is making unaudited financial information available to CFR Pharmaceutical SA so that CFR can comply with its reporting requirements, as CFR is releasing its interim results. The document itself contains a brief Balance Sheet and Income Statement summary for the 6 months ended 31 March 2014. Since this is a short announcement providing key financial data snippets and referencing another company's upcoming interim results release, it functions as a regulatory update or a preliminary release of data. Given the context of providing data to another entity for their reporting, and the presence of the RNS header, it fits best under the general 'Regulatory Filings' category (RNS), as it is not a comprehensive Interim Report (IR) itself, nor is it a formal Earnings Release (ER) for Allergy Therapeutics, but rather a specific shareholder/regulatory update.
2014-09-04 English
Notice of Results and Trading Update
Regulatory Filings Classification · 99% confidence The document is a short announcement (2506 characters) released via RNS (RNS Number : 1566N) titled "Notice of Results and Trading Update". It provides preliminary financial highlights (expected revenues of £45.7m) for the year ended 30 June 2014 and explicitly states that the preliminary results will be announced later on 22 September 2014. Because this document is an announcement about upcoming results rather than the full results themselves (which would likely be an IR or 10-K), and it is short and serves to update the market on performance ahead of a formal release, it fits the definition of an Earnings Release (ER) which provides key highlights only. Although it mentions the RNS service, the content is clearly focused on financial performance updates, making ER more specific than the general RNS fallback.
2014-07-24 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 6503M' and contains a standardized regulatory notification format titled 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES'. This form details changes in major shareholdings (crossing the 26.07% threshold) by an entity (SOUTHERN FOX INVESTMENTS LTD.). This type of filing, which reports changes in significant ownership, corresponds directly to the Major Shareholding Notification category. Although it is distributed via RNS, the specific content dictates the 'MRQ' classification over the general 'RNS' fallback.
2014-07-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.